BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank check company formed to pursue a business combination in the healthcare and life sciences sector. The company completed its initial public offering in 2021 and subsequently filed a definitive proxy statement (DEF 14A) with the SEC on May 12, 2023, indicating a shareholder vote related to its deal process. Focused squarely on the biotech and pharmaceutical space, BioPlus reflects a cohort of sector-specialist SPACs that targeted life sciences targets during an active period for healthcare-focused blank check vehicles. For complete filing history, deal timelines, warrant data, and real-time status updates on BioPlus Acquisition Corp. and thousands of other SPACs, create a free account at SpacDesk.